GHTF clarifies ethical considerations in clinical studies guidance
This article was originally published in Clinica
The Global Harmonization Task Force has underscored the significance of ethical considerations in the final version of its guidance on pre-market clinical investigations for medical devices. It has also provided clarifications on post-market clinical follow-up studies in a second guidance document.
You may also be interested in...
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.